Aqemia, a Paris, France-based tech-enabled drug discovery company, raised additional €30M in Series A funding.
The round, which brought the total amount to €60M, was led by Wendel Growth with participation from Bpifrance Large Venture, Eurazeo, and Elaia.
The company intends to use the funds to accelerate the growth of its wholly-owned pipeline of drug discovery projects and assets, as well as further scale its proprietary GenAI and physics drug discovery platform.
Led by CEO Maximilien Levesque, Aqemia is a pharmatech company generating a drug discovery pipeline, whose differentiation lies in its quantum and statistical mechanics algorithms fueling a generative artificial intelligence to design novel drug candidates. The company’s internal pipeline is already counting several projects being tested in animals, mostly in oncology and immuno-oncology, and the next phase of projects will cover the full spectrum of therapeutic areas.
Commenting on the news, Maximilien Levesque said: “We embark on this next chapter of our history to accelerate our drug discovery programs, to build a larger proprietary pipeline beyond our projects already tested in animals, and to shape a global organization that embraces generative AI and rigorous physics as key instruments to bring excellence in small molecule drug discovery. AQEMIA’s journey continues: We’re advancing to clinical trials.”
FinSMEs
30/01/2024